Hillgene Reached a Strategic Cooperation with Biotheus in Climbing to New Heights in China for CAB-T Cell Therapy Products

On August 14, 2021, Jiangsu Spectrum Biopharmaceutical Co., Ltd. (hereinafter referred to as "Spectrum Bio") and Promis Biotech Co., Ltd. (hereinafter referred to as "Promis") reached a comprehensive strategic cooperation on the commissioned development and production of cell therapy drugs.

Previously, Spectrum Bio and Promis had established a long-term and good cooperative relationship in the commissioned development and production projects of multiple new CAB-T cell therapy drugs. As the project continues to advance, the two parties will carry out comprehensive and in-depth strategic cooperation.

Promis is committed to the research and development of innovative biopharmaceuticals in the field of tumor immunotherapy. The preclinical data of the CAB-T cell therapy platform developed by it with independent intellectual property rights show that it has significant anti-tumor effects and is currently under clinical research. In this cooperation, Spectrum Bio will rely on its process development capabilities and cell drug GMP production capabilities as a provider of overall solutions for the industrialization of cell and gene therapy drugs to provide CDMO technical services for Promis's multiple new CAB-T cell drugs, including plasmid, lentivirus, and cell process production. The service stage covers from non-registered clinical (IIT) → clinical application (IND) → registered clinical sample production. The two parties will work together to advance the innovative CAB-T cell drug project to the next milestone as soon as possible and write a new chapter in cell and gene therapy!

Mr. Liu Xiaolin, founder of Promis, said: Spectrum Bio has helped several cell drug projects successfully obtain China's IND clinical trial license and has rich experience in CDMO services for cell therapy products. The advantages of the CAB-T cell therapy platform independently developed by Biosimi are: the CAB-T cell therapy platform optimizes and integrates the mechanisms of action of CAR-T, TCR-T and TCE (T cell engager), which can not only play an anti-tumor role by editing the cells themselves, but also play an anti-tumor role by mobilizing tumor-infiltrating T cells, which is expected to solve the clinical problem that the current CAR-T therapy has limited efficacy in treating solid tumors. This cooperation with Spectrum Bio can accelerate the industrialization process of our CAB-T cell therapy platform cell drug project and allow patients to benefit earlier.

Mr. Li Cha, CEO of Spectrum Bio, said: As a well-known innovative pharmaceutical company, Biosimi has high requirements for the professionalism of CDMO suppliers and requires them to fully understand cell drugs. It is a great honor to reach a comprehensive strategic cooperation with Biosimi. Cell drugs are "living" drugs, including stem cells and various immune cells. They are one of the most complex drug forms and play a unique role in the treatment of many diseases. The future market is worth hundreds of billions of dollars. However, how cells become "drugs" is complex and unique. As the most professional cell drug CDMO service provider, Spectrum Bio's service cases include universal CAR-T, TCR-T, stem cell drugs, etc., providing full-process solutions for cell drugs for many well-known pharmaceutical companies. Through this cooperation, Spectrum Bio will be committed to advancing the innovative CAB-T cell drug series product pipeline of Promis to the next milestone, and write a new chapter in cell and gene therapy in China!

About Promis

Founded in 2018, Promis has always adhered to the entrepreneurial mission of "lighting up the spark of innovation and achieving a healthy life", focusing on malignant tumors and autoimmune diseases, and is committed to the research and development and industrialization of national Class I innovative biological drugs. Promis has now built a product pipeline of more than 10 national Class I biological new drugs, including monoclonal antibodies and bispecific antibodies. Among them, 4 anti-tumor new drugs are undergoing Phase I-II clinical studies, and the fifth new drug project has submitted a clinical trial application in June 2021. In the future, Promis will continue to increase its R&D investment, and it is expected that more new drug products will enter the clinical research stage by the end of 2021.

About Spectrum Bio

Spectrum Bio is positioned as a global leading provider of overall solutions for the industrialization of cell and gene therapy drugs. The company is headquartered in Wuzhong District, Suzhou City, on the beautiful shore of Taihu Lake, with a registered capital of 100 million yuan. The company has a Suzhou headquarters (7000m2 GMP plant) and a Zhengzhou base (7000m2 GMP plant under construction), initially forming a nationwide production base network layout.

Spectrum Bio, a one-stop service platform for cell and gene therapy CDMO, focuses on the field of cell and gene therapy drugs, and has built a nucleic acid product process development platform, a suspended serum-free virus culture platform and a fully enclosed cell process development platform, creating a highway from drug discovery to product delivery. The platform has supported multiple partners to successfully incubate a number of CAR-T, TCR-T, stem cells, mRNA and other drugs. It is committed to enabling more projects to reach the next milestone earlier and faster, bringing more cell and gene therapy drugs to the market, benefiting more patients, and writing a new chapter in cell and gene therapy in China.